Venturis Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics aimed at treating various vascular dysfunction-related diseases, including diabetic wounds, severe ischemic heart disease, and peripheral artery disease. The company employs human proteins from the Fibroblast Growth Factor family, which are pivotal in stimulating the growth of new blood vessels in ischemic tissues. Their lead therapeutic candidate, Vascu-Grow™, is designed to enhance angiogenesis, thereby improving blood flow and healing in affected areas. Venturis is actively advancing multiple preclinical programs targeting conditions such as erectile dysfunction, infarct stroke, degenerative disk disease, and Parkinson’s Disease, showcasing a broad commitment to addressing significant medical needs.

The company has established a robust pipeline with three open Investigational New Drug (IND) applications with the U.S. Food and Drug Administration, alongside four preclinical programs. Their clinical stage programs include Vascu-Grow™ for chronic diabetic foot ulcers, coronary artery disease, and peripheral arterial disease, all of which are in various phases of development. Additionally, Venturis is exploring other therapeutic candidates aimed at conditions like ischemic disc disease and erectile dysfunction, indicating a comprehensive approach to tackling a range of vascular-related health issues. The strategic alliances and patent applications further underscore their commitment to advancing therapeutic angiogenesis as a viable treatment strategy.

United States

Venturis Therapeutics, Inc is a clinical stage bio-pharmaceutical company advancing novel therapeutics utilizing regenerative medicine to address diseases such as diabetic foot ulcers (DFU), severe ischemic heart disease, and peripheral artery disease (PAD) by regrowing the microvascular circulation (angiogenesis)

Venturis Therapeutics

Company Details